State lawmakers Feb. 22 introduced A.B. 150 to limit the diversion of pseudoephedrine-containing OTC medicines to methamphetamine production by requiring prescriptions for the products, along with those made with ephedrine and phenylpropanolamine. The Consumer Healthcare Products Association strongly opposes the bill and will express its concerns in Nevada the week of Feb. 26. The bill is modeled after a 2005 Oregon law (1"The Tan Sheet" Aug. 22, 2005, p. 5). The Bush administration has said it will monitor the effectiveness of behind-the counter provisions of the federal Combat Meth Act as well as stricter state strategies (2"The Tan Sheet" June 12, 2006, p. 6)...
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
A government-backed program is working on improving the ability to run dementia clinical trials in the UK, and access to trials for participants.
Vinay Prasad’s exit from the US FDA reignited conversations about integrating its drugs and biologics centers under George Tidmarsh. Those plans appear to be shelved, but the leadership transition could be an opportunity to fully realize the vision for the Oncology Center of Excellence.
The Pink Sheet viewed Stealth's complete response letter and other documents indicating the FDA appears willing to grant accelerated approval to elamipretide before a confirmatory trial begins enrolling. But the company says it needs a two-month review of the NDA resubmission to survive.
